MedTrace Logo

Recanalization Rate of Acute DVT

NCT06145269 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-11-24

No results posted yet for this study

Summary

Rporting and evaluation of the rate of recanalization of acute DVT of the lower limb at one year follow-up comparing the results of using NOACs vs. conventional treatment.

Conditions

  • Acute DVT of Lower Extremity

Interventions

DRUG

New oral anticoagulant (rivaroxaban) and Marevan (warfarin)

comparison between 2 drug, (rivaroxaban) and Marevan (warfarin)

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-01
Primary Completion
2025-04-01
Completion
2025-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06145269 on ClinicalTrials.gov